Business Wire

NTT-DATA

18.7.2024 14:01:34 CEST | Business Wire | Press release

Share
NTT DATA Unveils Ultralight Edge AI Platform

NTT DATA, a leading IT infrastructure and services company, unveiled its new Edge AI platform to accelerate IT/OT convergence by bringing AI processing to the edge. By processing data when and where it is generated and unifying diverse IoT devices, systems and data, this unique, fully managed solution enables real-time decisions, enhanced operational efficiencies and secure AI application deployment across industries to drive advanced Industry 4.0 technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718015818/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

NTT DATA unveiled a new ultralight Edge AI platform, a fully managed service that allows enterprises to deploy AI applications at the edge using smaller, more efficient language learning models that deliver immediate AI insights. [Source: NTT DATA]

While the spotlight has been on GenAI and Large Language Models (LLMs), these technologies are impractical for industries requiring real-time and local decision-making. NTT DATA’s Edge AI solution addresses this challenge by processing massive data sets on compact computing platforms, using smaller, more efficient machine learning models to deliver real-time AI insights.

NTT DATA’s Edge AI is an all-inclusive managed service platform that includes all the systems, tools and capabilities required for AI at the edge. It addresses data discovery, collection, integration, computation power, seamless connectivity and AI model management.

The Edge AI platform, supported by NTT DATA’s consulting data scientists, managed services and global technical resources, addresses the shadow IoT challenge and AI infrastructure requirements. It does this by auto-discovering, unifying and processing data from IoT devices and IT assets across the organization, simplifying AI deployment and management.

Solving industry-specific challenges with AI-driven insights

Designed to support industry-specific requirements, the Edge AI platform leverages lighter, cost-effective AI models, enabling it to run within a small compute box. Edge AI will perform specific tasks, such as supporting safety or operational efficiency, by collecting data from disparate devices across a network environment, enabling instantaneous and secure data processing and analytics.

Manufacturing operations could benefit from improved predictive maintenance by accessing IT/OT data from sensors, machinery, cameras and applications to plan and address failures. In addition, NTT DATA’s Edge AI can monitor and optimize energy consumption in real time, predicting energy spikes and optimizing machine usage, reducing costs and CO2 emissions with renewable energy.

“Our Edge AI platform represents a significant leap forward in driving AI at the edge securely and cost-effectively,” said Shahid Ahmed, Group Executive Vice President of Edge Services at NTT DATA. “By harmonizing data from disparate sensors and devices with lightweight AI models, powering all kinds of automation use-cases, NTT DATA’s Edge AI is pioneering industrial AI adoption as the first fully managed offering, helping organizations modernize with tailored, industry-specific solutions.”

Seizing the US$200 billion market opportunity

According to IDC, worldwide spending on edge computing is expected to reach US$232 billion in 2024, an increase of 15% over 2023. This growth is perpetuated by the growing number of connected IoT devices worldwide, expected to exceed 41 billion by 2025.

NTT DATA is poised to capture significant market share through its dedicated IoT consulting and services business, which brings together 1,000 industry experts, hundreds of use cases from predictive maintenance, fleet management, connected factories, energy consumption monitoring and sustainability, and has already trained over 500 sales experts globally to accelerate its Edge AI go-to-market efforts.

NTT DATA’s Edge AI deployment approach allows clients to take advantage of a free 30-day discovery and diagnostic of their IT and OT environment. The software auto-discovers assets with its vast library of pre-built OT interfaces. After this initial stage, Edge AI software generates a comprehensive diagnostic report inventorying assets and data streams, including identifying security risks and vulnerabilities.

“A key challenge for enterprises is reliably capturing and aggregating operational data securely across a fragmented landscape of devices, platforms and data sources and turning it into actionable insights,” said Alejandro Cadenas, Associate Vice President, Telco Mobility & IoT Research, IDC Europe. “NTT DATA’s ultralight Edge AI addresses these issues and simplifies the deployment and adoption of a data-driven enterprise strategy, reducing risks and timelines and optimizing total cost of ownership and value for the enterprise."

Driving secure AI adoption at the edge with the first fully managed service

NTT DATA’s managed services for Edge AI offer a unified view and management of devices, sensors and assets. With expert support and advanced technologies, NTT DATA helps businesses simplify complex processes, drive cost savings, enhance performance and accelerate digital transformation.

As the industry’s first fully managed IT/OT convergence platform, Edge AI transforms physical assets into software assets for data-driven insights, regardless of the manufacturer. Operating at the edge, managed services integrate OT assets with IT applications, boosting operational efficiency. Edge AI also provides a view of the firmware version of all connected devices to promote vulnerability patching and overall device security.

“Computing and AI must happen where they create the most value for the enterprise; for many industrial enterprises this is where the data is generated. By ingesting IT and OT data and leveraging AI models to drive use-case specific results, the NTT DATA solution takes another step towards realizing the industry 4.0 vision,” said Pablo Tomasi, Principal Analyst, Private Network, Omdia. “Additionally, using task-specific small AI models will help drive AI democratization by making it is easier for the enterprise to introduce AI where and when is needed, without the need for an extensive overhaul of their whole infrastructure.”

Edge AI rounds out NTT DATA’s comprehensive Edge portfolio, which includes Enterprise IoT, Edge Compute, Private 5G and Device as a Service.

About NTT DATA

NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718015818/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye